GeneDx Holdings (WGS) Earnings Date & Reports

Key Takeaways

• GeneDx reported total revenue of $114.4 million for the second quarter of 2026, up 11% year over year and above consensus estimates.
• Exome and genome test volume reached a record 30,785 tests, up 32% year over year, driving exome and genome revenue of $100.3 million (up 17%).
• The company returned to adjusted net income of $0.4 million, reaching profitability one quarter earlier than management had guided.
• On a GAAP (Generally Accepted Accounting Principles) basis, the company swung to a net loss of $17.7 million, or $0.60 per share.
• Adjusted EPS (earnings per share) of $0.01 beat the consensus estimate, which had called for a loss of $0.19 per share.
• Management reaffirmed full-year 2026 guidance, including $475–$490 million in revenue and at least 30% exome and genome volume growth.
• For additional context, explore this ticker's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover AI-driven trading strategies by exploring Trending AI Robots.

Earnings Context and Why It Matters

GeneDx Holdings Corp. is a genomics company focused on exome and genome sequencing for the diagnosis of rare diseases, and its quarterly results serve as a key barometer for how quickly genetic testing is being adopted as a first-line diagnostic tool. The second quarter of 2026 was especially important because the company had lowered its full-year revenue outlook earlier in the year, leaving investors eager for evidence that demand remained intact. Record test volume, a return to adjusted profitability, and reaffirmed guidance offered that reassurance. At the same time, the widening GAAP net loss highlighted that scaling a high-growth testing business still carries meaningful cost and reimbursement pressures.

Reported Results

GeneDx reported total revenue of $114.4 million for the second quarter of 2026, an 11% increase from $102.69 million in the prior-year period and above consensus estimates. Exome and genome revenue rose 17% year over year to $100.3 million, supported by a record 30,785 exome and genome tests, up 32%.

Gross margin improved to 70%, up from 69% in the first quarter. The company generated adjusted net income of $0.4 million, an $8.6 million sequential improvement that brought profitability back one quarter ahead of schedule. Adjusted EPS of $0.01 comfortably exceeded the consensus forecast for a loss of $0.19 per share.

On a GAAP basis, however, GeneDx reported a net loss of $17.7 million, or $0.60 per share, compared with net income of $10.81 million in the same quarter a year earlier. The blended average reimbursement rate (ARR) was $3,258 per test, roughly flat quarter over quarter. The company also expanded its debt facility by $50 million, bringing pro forma liquidity to about $188 million, and reaffirmed its full-year 2026 outlook.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for investors monitoring earnings-driven movers like WGS.

Market Reaction and Investor Sentiment

Shares of GeneDx Holdings climbed following the second-quarter report, with traders responding positively to the earnings and revenue beats, the record test volume, and the earlier-than-expected return to adjusted profitability. Sentiment was also supported by management's decision to reaffirm full-year guidance, which eased concerns that the prior reduction in the revenue outlook signaled weakening demand. At the same time, the wider GAAP net loss and a blended average reimbursement rate that remained flat quarter over quarter kept some caution in the conversation, as investors weighed strong top-line momentum against ongoing cost and reimbursement headwinds.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether GeneDx can sustain its volume growth while improving the economics of each test. The company has signaled that meaningful improvements in collection rates are expected in the fourth quarter of 2026 and into 2027, which makes reimbursement trends a central focus for future quarters.

Another area to monitor is the mix between exome and genome testing. Genome tests carry a lower collection rate today, so any shift in mix could influence both revenue growth and gross margin. Management's efforts to expand payer coverage, refine payer-specific workflows, and deploy AI-driven revenue cycle tools will be key to converting higher volumes into stronger reported profitability.

Finally, watch for continued traction in newer commercial channels such as general pediatrics and prenatal testing, which offer additional growth runway. With full-year 2026 guidance reaffirmed at $475–$490 million in revenue and at least 30% exome and genome volume growth, the balance between expansion and cost discipline will likely shape how the market evaluates the stock over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations